


# PRODUCT INFORMATION



## (±)-SLV 319

Item No. 10009226

**CAS Registry No.:** 362519-49-1  
**Formal Name:** 3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N'-methyl-4-phenyl-1H-pyrazole-1-carboximidamide  
**MF:** C<sub>23</sub>H<sub>20</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S  
**FW:** 487.4  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 204, 228, 313 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

(±)-SLV 319 is supplied as a crystalline solid. A stock solution may be made by dissolving the (±)-SLV 319 in an organic solvent purged with an inert gas. (±)-SLV 319 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of (±)-SLV 319 in these solvents is approximately 30 mg/ml.

(±)-SLV 319 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, (±)-SLV 319 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. (±)-SLV 319 has a solubility of approximately 0.25 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Central cannabinoid (CB<sub>1</sub>) receptor antagonists may have potential in the treatment of a number of diseases such as neuroinflammatory disorders, cognitive disorders, septic shock, obesity, psychosis, addiction, and gastrointestinal disorders.<sup>1</sup> (±)-SLV 319 is the mixture of the CB<sub>1</sub> receptor antagonist SLV 319 and its distomer, SLV 319 (+)-enantiomer. SLV 319 is a potent and selective CB<sub>1</sub> receptor antagonist with K<sub>i</sub> values of 7.8 and 7,943 nM for CB<sub>1</sub> and peripheral cannabinoid (CB<sub>2</sub>), respectively.<sup>1</sup> SLV 319 is less lipophilic (log P = 5.1) and therefore more water soluble than other known CB<sub>1</sub> receptor ligands.<sup>2</sup>

### References

1. Lange, J.H.M., Coolen, H.K.A.C., van Stuivenberg, H.H., *et al.* Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB<sub>1</sub> cannabinoid receptor antagonists. *J. Med. Chem.* **47**(3), 627-643 (2004).
2. Lange, J.H.M., van Stuivenberg, H.H., Veerman, W., *et al.* Novel 3,4-diarylpyrazolines as potent cannabinoid CB<sub>1</sub> receptor antagonists with lower lipophilicity. *Bioorg. Med. Chem. Lett.* **15**(21), 4794-4798 (2005).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/25/2024

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM